logo
  

Celyad Oncology Discontinues Autologous CAR T Candidate CYAD-01; CYCLE-1 CYAD-02 Trial Ongoing

Celyad Oncology SA (CYAD), a clinical-stage biotechnology company focused on chimeric antigen receptor T cell or CAR T therapies for cancer, issued Monday updates on allogeneic and autologous CAR T Programs.

The updates from the company's shRNA-based anti-B cell maturation antigen or BCMA allogeneic CAR T candidate, CYAD-211, and autologous NKG2D receptor-based CAR T candidates, CYAD-01 and CYAD-02, were virtually presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

The company said it is disappointed in its update from the Phase 1 THINK trial for first-generation, autologous CAR T candidate CYAD-01 and discontinues its development based on clinical futility observed to date from the Phase 1 THINK trial.

Meanwhile, preliminary data from CYCLE-1 trial evaluating next-generation autologous CYAD-02 in r/r AML / MDS patients showed encouraging clinical signals, including a high-risk MDS patient treated at dose level 3 who achieved an objective marrow complete response. The company said dose level 3 cohort of the CYCLE-1 trial is ongoing.

The company noted the dosing of first patient with CYAD-211 Phase 1 IMMUNICY-1 trial. Preclinical results for CYAD-211 for multiple myeloma showed robust antitumor activity with no demonstrable evidence of Graft-versus-Host Disease.

Filippo Petti, Chief Executive Officer of Celyad Oncology, said, "While we are disappointed by the latest update from the Phase 1 THINK trial for CYAD-01, we are encouraged by the initial clinical results from our next-generation CYAD-02 candidate for the treatment of patients with relapsed or refractory AML and MDS and look forward to future updates from the CYCLE-1 trial."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home improvement retailer Lowe's Cos., Inc. reported Wednesday an increase in earnings per share for the second quarter that also topped analysts' estimates. However, quarterly sales edged down and missed expectations. The company also reaffirmed its guidance range for the full-year 2022. While reporting financial results for the second quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided financial outlook for the third and the fourth quarters as well as slashed its guidance for the full-year 2023. For the third quarter, the company projects earnings in a range... American Airlines announced an agreement to purchase up to 20 Overture supersonic jets, the world's fastest airliner, from transportation start-up Boom Supersonic, with an option for an additional 40. Overture, which is expected to carry passengers at twice the speed of the fastest commercial aircraft available at present, would provide an important new speed advantage to American's fleet.
RELATED NEWS
Follow RTT